Dr Reddy’s Q3 results: Dr Reddy’s Laboratories is set to release its earnings for the December quarter later today. The company is expected to see a muted growth in revenue amid lower sales of generic anti-cancer drug Revlimid and moderate growth in India business. Higher raw material inflation is seen hurting the profitability. Analysts and investors will closely track management comments on outlook for the US, Russia, and India markets, planned product launches for FY25, and research and development spending of the company.
